An observational study in Knee Osteoarthritis, sponsored by Hopital Nord Franche-Comte. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by Hopital Nord Franche-Comte · Observational
Knee osteoarthritis is a frequent condition whose prevalence is estimated at 7.6% of the French population aged 40 to 75, or approximately 2 million individuals . Viscosupplementation (VS) is a symptomatic treatment of knee osteoarthritis recommended by a large number of learned societies. It consists of the intra-articular injection (IA) of hyaluronic acid (HA), to reduce knee pain by restoring normal joint homeostasis impaired by endogenous HA deficiency.
The IA administration of HA can be performed using 2 protocols: repeated weekly injections (3, sometimes 5 injections) and single injections. To date and there is no argument to favor either protocol. Regardless of the formula used, the safety of HA is excellent (RR of adverse reaction versus saline = 1.01, 95% CI 0.96-1.07, P = 0.6). The indication for viscosupplementation is the symptomatic treatment of mild to moderate knee osteoarthritis after failure and / or intolerance of analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs). In this indication, after HA injection the responder rate is in the order of 70% to 75% at 6 months and approximately 50% at 12 months. However, the predictors of the duration of effectiveness of SV are still unknown. The objective of the study is to research the factors influencing the duration of the effectiveness of SV, under real life conditions.
4,397 studies on the registry are indexed under Osteoarthritis; 581 are open to participants now.
This study's enrollment of 103 is close to the median of 100 across 790 observational studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Hopital Nord Franche-Comte is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A questionnaire is administered by the investigator during the medical consultation. No act is performed outside of patient care.
Exclusion Criteria:
none intervention
Investigate the factors influencing the duration of the effectiveness of SV, under real-life conditions
Duration (in weeks) during which the patient was satisfied with the treatment
Time frame: At inclusion
Research for predictive factors will be carried out on the duration of satisfaction
Research for predictive factors will be carried out on the duration of satisfaction
Time frame: At inclusion
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopital Nord Franche-Comte